



With the exception of any logos and registered trademarks, and where otherwise noted, all material presented in this document is provided under a Creative Commons Attribution 4.0 license (https://creativecommons.org/licenses/by/4.0/)

The details of the relevant license conditions are available on the Creative Commons website (accessible using the links provided) as is the full legal code for the CC BY 4.0 license (https://creativecommons.org/licenses/by/4.0/legalcode)

The content obtained from this document or derivative of this work must be attributed as:

Australian Haemovigilance Report, Data for 2019-20 published by the National Blood Authority.

ISSN 1838-1790

This report is available online at www.blood.gov.au/haemovigilance-reporting

Contact officer:

Haemovigilance

Locked Bag 8430

Canberra ACT 2601

Phone: +61 2 6151 5000

Fax: +61 2 6151 5300

Email: [haemovigilance@blood.gov.au](mailto:haemovigilance@blood.gov.au)

Website: www.blood.gov.au

# TABLE OF CONTENTS

[TABLE OF CONTENTS 3](#_Toc127166420)

[SECTION 1 5](#_Toc127166421)

[Australian Haemovigilance Data 5](#_Toc127166422)

[Acknowledgements 5](#_Toc127166423)

[Caveats 5](#_Toc127166424)

[Collection and reporting process 5](#_Toc127166425)

[Introduction 6](#_Toc127166426)

[Results for all adverse events, 2015-16 to 2019-20 7](#_Toc127166427)

[Results for all adverse events, 2019-20 8](#_Toc127166428)

[Contributory factors for all adverse events, 2015-16 to 2019-20 13](#_Toc127166429)

[Contributory factors for all adverse events for 2019-20 13](#_Toc127166430)

[Classification of adverse events 14](#_Toc127166431)

[Hospital participation in haemovigilance reporting 16](#_Toc127166432)

[2015-16 to 2019-20 reclassified 17](#_Toc127166433)

[Recommendations 21](#_Toc127166434)

[SECTION 2 22](#_Toc127166439)

[**Donor Vigilance Report 2019-2020** 22](#_Toc127166440)

[APPENDIXES 34](#_Toc127166455)

[Appendix 1: Glossary 34](#_Toc127166456)

[Appendix 2: State/territory haemovigilance process improvement 35](#_Toc127166457)

[ABBREVIATIONS 37](#_Toc127166466)

[ACKNOWLEDGEMENTS LIST 38](#_Toc127166467)

# SECTION 1

# Australian Haemovigilance Data

**July 2019 – June 2020**

### Acknowledgements

This report is published on behalf of the states and territories who voluntarily provided data to the national program. The National Blood Authority (NBA) thanks them for their contributions and ongoing commitment to haemovigilance.

Appreciation is also extended to the members of the Haemovigilance Advisory Committee (HAC) for their advice on improvements in adverse event reporting and analysis of the data for this report.

### Caveats

Reporting of haemovigilance data to the national haemovigilance program is voluntary and data validation is not performed in all instances in Australia.

When using the data from this report it is important to note that there are quality issues in relation to data completeness, standardisation, and relevance.

Notwithstanding these limitations, the NBA is publishing this data as an aid to relevant analysis and to maintain the time series of data published during the last ten years.

* Data in this report are in accordance with either the National Blood Authority National Haemovigilance Data Dictionary (NHDD) 2010 or the Australian Haemovigilance Minimum Data Set (AHMDS) 2015. The definitions for the adverse events in **Appendix I** of the 2010 NHDD and 2015 AHMDS align with those used by the International Haemovigilance Network (IHN) and International Society Blood Transfusion (ISBT) unless otherwise stated. However, it is not expected that they are applied rigorously.
* All states and territories except QLD reported the data in line with the 2015 AHMDS for 2019-20. QLD uses the 2010 NHDD except for the imputability scores which are based on the 2015 AHMDS.
* All states and territories have contributed to the data since 2015-16. However, the level and data provided vary across years and between states and territories.
* The use of different haemovigilance reporting processes across the jurisdictions which may lead to data inconsistencies.
* Near misses and denominator data (number of transfusions) are not collected and reported at a national level.
* All the 2019-20 transfusion-transmitted infection (TTI) data have been verified with the states and territories and Australian Red Cross Lifeblood (Lifeblood).
* The Serious Transfusion Incident Reporting (STIR) used a higher-level temperature threshold for the reporting of febrile non-haemolytic transfusion reaction (FNHTR) before 2018-19.

### Collection and reporting process

In Australia, haemovigilance is undertaken at local or state/territory, supported by a national data collection and reporting process. Data is collected at the local or state/territory level and the local area is responsible for the review of reported incidents to assess the validity and imputability of the incident with respect to whether it was reported correctly, the seriousness of the incident, and assessment of the cause of the incident being related to the transfusion. Some states and territories/local organisations provide their data to STIR to conduct this review, while others manage this process themselves, or do not do a review outside of the local level. Following review, the data is validated in line with the AHMDS before reporting the data to the NBA.

**Note: NSQHS – National Safety and Quality Health Service, TGA – Therapeutic Goods Administration**

### Introduction

States and territories use different haemovigilance reporting processes which may lead to different number of adverse events reported to the national haemovigilance program. For example, the Victorian Blood Matters Serious Transfusion Incident Reporting (STIR) for participating states (VIC, TAS, NT and ACT), reports serious adverse events and excludes non-transfusion related adverse events. QLD reports all adverse events according to the definitions of these and does not exclude non-transfusion related adverse events.

The report commences with data on all events reported to the NBA, and then for consistency and comparability, events have been categorised as non-transfusion related adverse events; transfusion‑related non-serious adverse events, and transfusion-related serious adverse events.

### Results for all adverse events, 2015-16 to 2019-20

This section presents the data and key results for all adverse events from 2015-16 to 2019-20.

**Table 1** shows that:

* all states and territories except NT reported an increase in adverse events in 2019‑20, with VIC increasing by 63.8% and NSW by 55.6%
* the adverse event rate per 100,000 population ranges from 1.12 for TAS to 5.83 for QLD in 2019‑20
* the use of different haemovigilance reporting processes across the jurisdictions which may lead to data inconsistencies.

**Table 1: All adverse events by state, 2015-16 to 2019-20**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **2015-16** | **2016-17** | **2017-18** | **2018-19** | **2019-20** |  | **‑** |  | |
|  |  |  |  |  |  | **Percent** | **Rate per 100,000 population** | | **% Change from 2018-19** |
| NSW | 281 | 175 | 61 | 72 | 112 | 16.6% | 1.38 | | 55.6% |
| VIC | 54 | 69 | 57 | 58 | 95 | 14.1% | 1.43 | | 63.8% |
| QLD | 250 | 246 | 202 | 233 | 299 | 44.3% | 5.83 | | 28.3% |
| SA | 62 | 54 | 61 | 52 | 69 | 10.2% | 3.92 | | 32.7% |
| WA | 73 | 71 | 85 | 68 | 83 | 12.3% | 3.15 | | 22.1% |
| TAS | 0 | 5 | 11 | 0 | 6 | 0.9% | 1.12 | | NA |
| NT | 3 | 5 | 2 | 12 | 5 | 0.7% | 2.04 | | -58.3% |
| ACT | 1 | 3 | 9 | 5 | 6 | 0.9% | 1.40 | | 20.0% |
| **Total** | **724** | **628** | **488** | **500** | **675** | **100%** | **2.65** | | **35.0%** |

**Note: The population data is from the ABS 31010DO001\_201912 Australian Demographic Statistics, Dec 2019**

**Table 2** shows that:

* the most common adverse events reported are febrile non-haemolytic transfusion reaction (FNHTR) and allergic reaction (Allergic) by percentage, population, and incidence rate
* transfusion-associated circulatory overload (TACO) is likely to be under-reported when the number of reports is compared with the incidence rate
* reported transfusion-transmitted infections (TTI) and incorrect blood component transfused (IBCT) increased by 300% (n=9) and 182% (n=20) respectively in 2019-20 compared to small numbers in 2018-19
* adverse events such as delayed serologic transfusion reaction (DSTR), hypotensive reaction (Hypotensive) and transfusion associated dyspnoea (TAD) have been reported from 2017-18 in line with the 2015 AHMDS.

**Table 2: All adverse events and incidence data, 2015-16 to 2019-20**



**Notes**

1. **The population data is from the ABS 31010DO001\_201912 Australian Demographic Statistics, Dec 2019**
2. **\*Australian Red Cross Lifeblood (2020), Blood Component Information: An extension of blood component labels**

**Table 3** showsthat most adverse events were reported by public hospitals. For more information, refer to the **Hospital participation in haemovigilance program** section.

**Table 3: All adverse events by hospital type, 2015-16 to 2019-20**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **2015-16** | **2016-17** | **2017-18** | **2018-19** | **2019-20** | **2019-20** | | |
|  |  |  |  |  |  | **Percent** | **Rate per 100,000 population** | **% Change from 2018-19** |
| Public hospital | 653 | 588 | 454 | 429 | 617 | 91.4% | 2.42 | 90.9% |
| Private hospitals | 71 | 40 | 34 | 71 | 58 | 8.6% | 0.23 | 9.1% |
| **Total hospitals** | **724** | **628** | **488** | **500** | **675** | **100%** | **2.65** | **100.0%** |

**Note: The population data is from the ABS 31010DO001\_201912 Australian Demographic Statistics, Dec 2019**

### Results for all adverse events, 2019-20

This section presents the data and key results for all reported adverse events for 2019-20.

**Table 4** shows that the percentages of red blood cell (RBC) issued from the Australian Red Cross Lifeblood (Lifeblood) are reasonably consistent with the population percentage for each state and territory. In contrast, QLD reported a much higher percentage of adverse events (44.3%) when compared with the population percentage and RBC issue percentage. This is mainly for FNHTRs (154) and allergic reactions (96). NSW reported less TACOs (6 out of 60) than VIC, QLD, and SA, and more IBCTs (16 out of 31) than other states and territories. The use of different haemovigilance reporting processes across the jurisdictions which may lead to data inconsistencies.

**Table 4: All adverse events by state, 2019-20**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Allergic** | **FNHTR** | **TACO** | **IBCT** | **Anaphylactic** | **DHTR** | **AHTR** | **TTI** | **TRALI** | **DSTR** | **Hypotensive** | **ABO** | **TAD** | **Other** | **All reports** | | **Population** | **Red blood cell issues** |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | **Total** | **Percent** | **Percent** | **Percent** |
| NSW | 51 | 28 | 6 | 16 | 0 | 0 | 2 | 3 | 1 | 0 | 3 | 0 | 2 | 0 | 112 | 16.6% | 31.9% | 31.4% |
| VIC | 17 | 16 | 15 | 5 | 9 | 7 | 2 | 0 | 1 | 19 | 0 | 0 | 2 | 2 | 95 | 14.1% | 26.1% | 27.1% |
| QLD | 96 | 154 | 14 | 5 | 6 | 6 | 13 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 299 | 44.3% | 20.1% | 20.8% |
| SA | 40 | 2 | 16 | 1 | 2 | 3 | 4 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 69 | 10.2% | 6.9% | 8.6% |
| WA | 35 | 16 | 5 | 3 | 7 | 2 | 2 | 3 | 0 | 6 | 0 | 1 | 1 | 2 | 83 | 12.3% | 10.3% | 8.0% |
| TAS | 1 | 2 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 6 | 0.9% | 2.1% | 2.0% |
| NT | 1 | 2 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 0.7% | 1.0% | 0.6% |
| ACT | 0 | 2 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 6 | 0.9% | 1.7% | 1.5% |
| **Total** | **241** | **222** | **60** | **31** | **24** | **18** | **24** | **12** | **2** | **25** | **3** | **1** | **7** | **5** | **675** | **100%** | **100%** | **100%** |

**Note: The population data is from the ABS 31010DO001\_201 912 Australian Demographic Statistics, Dec 2019**

**Table 5: All adverse events by imputability score, 2019-20**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Event type** | **Excluded** | **Unlikely** | **Possible** | **Probable (likely)** | **Definite (certain)** | **Not assessable** | **Total** | **Percent** |
| FNHTR | 5 | 40 | 122 | 40 | 2 | 13 | 222 | 32.9% |
| Allergic | 2 | 1 | 55 | 131 | 50 | 2 | 241 | 35.7% |
| TACO | 0 | 1 | 19 | 23 | 13 | 4 | 60 | 8.9% |
| IBCT | 0 | 0 | 1 | 0 | 25 | 5 | 31 | 4.6% |
| Anaphylactic | 0 | 0 | 12 | 9 | 3 | 0 | 24 | 3.6% |
| DHTR | 0 | 0 | 4 | 4 | 10 | 0 | 18 | 2.7% |
| AHTR | 0 | 1 | 8 | 6 | 6 | 3 | 24 | 3.6% |
| TTI | 2 | 0 | 2 | 2 | 2 | 4 | 12 | 1.8% |
| TRALI | 0 | 0 | 1 | 1 | 0 | 0 | 2 | 0.3% |
| DSTR | 0 | 0 | 1 | 7 | 17 | 0 | 25 | 3.7% |
| Hypotensive | 0 | 0 | 2 | 0 | 0 | 1 | 3 | 0.4% |
| ABO | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0.1% |
| TAD | 0 | 0 | 3 | 2 | 0 | 2 | 7 | 1.0% |
| Other | 0 | 0 | 4 | 0 | 1 | 0 | 5 | 0.7% |
| **Total** | **9** | **43** | **234** | **225** | **130** | **34** | **675** |  |
| **Percent** | **1.3%** | **6.4%** | **34.7%** | **33.3%** | **19.3%** | **5.0%** | **100%** |  |

**Note: QLD reported most of the non-transfusion related FNHTRs**

**Table 5** shows that 87.3% (589) of reported adverse events (imputability=possible, likely, and definite) are related to blood transfusion. Non transfusion related adverse events (imputability=‑excluded, unlikely, and not assessable) accounted for 12.7% (86) and should be excluded from analysis.

A breakdown of adverse events by clinical outcome severity in shows:

* of the three deaths reported, only one (anaphylactic) death related to transfusion
* life-threatening and severe morbidity events accounted for 11.6% of total reports
* 63.1% of reported adverse events related to minor morbidities.

**Table 6: All adverse events by clinical outcome severity, 2019-20**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Adverse event** | **Death** | **Life-threatening** | **Severe morbidity** | **Minor morbidity** | **No morbidity** | **Outcome not available** | **Total** |
| FNHTR | 1 | 1 | 12 | 167 | 32 | 9 | 222 |
| Allergic | 0 | 9 | 5 | 186 | 40 | 1 | 241 |
| TACO | 0 | 8 | 12 | 31 | 8 | 1 | 60 |
| IBCT | 1 | 1 | 2 | 2 | 15 | 10 | 31 |
| Anaphylactic | 1 | 11 | 5 | 2 | 5 | 0 | 24 |
| DHTR | 0 | 0 | 1 | 12 | 4 | 1 | 18 |
| AHTR | 0 | 3 | 1 | 18 | 2 | 0 | 24 |
| TTI | 0 | 3 | 1 | 0 | 5 | 3 | 12 |
| TRALI | 0 | 2 | 0 | 0 | 0 | 0 | 2 |
| DSTR | 0 | 0 | 0 | 2 | 23 | 0 | 25 |
| Hypotensive | 0 | 0 | 0 | 1 | 1 | 1 | 3 |
| ABO | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| TAD | 0 | 1 | 0 | 3 | 2 | 1 | 7 |
| Other | 0 | 0 | 0 | 1 | 4 | 0 | 5 |
| **Total** | **3** | **39** | **39** | **426** | **141** | **27** | **675** |
| **Percent** | **0.4%** | **5.8%** | **5.8%** | **63.1%** | **20.9%** | **4.0%** | **100%** |

**Table 7** highlights that 61.5% of adverse events were reported to be red cell transfusions, followed by platelets (24.7%) and fresh frozen plasma (10.2%).

**Table 7: All adverse events by blood product, 2019-20**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Adverse event** | **Red cells** | **Platelets** | **Fresh frozen plasma** | **Cryoprecipitate** | **Cryo-depleted Plasma** | **Multiple products** | **Other products** | **Total** |
| FNHTR | 192 | 28 | 2 | 0 | 0 | 0 | 0 | 222 |
| Allergic | 61 | 103 | 57 | 9 | 4 | 5 | 2 | 241 |
| TACO | 56 | 2 | 2 | 0 | 0 | 0 | 0 | 60 |
| IBCT | 27 | 2 | 1 | 1 | 0 | 0 | 0 | 31 |
| Anaphylactic | 6 | 10 | 6 | 2 | 0 | 0 | 0 | 24 |
| DHTR | 16 | 1 | 0 | 0 | 0 | 0 | 1 | 18 |
| AHTR | 16 | 8 | 0 | 0 | 0 | 0 | 0 | 24 |
| TTI | 1 | 11 | 0 | 0 | 0 | 0 | 0 | 12 |
| TRALI | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| DSTR | 24 | 1 | 0 | 0 | 0 | 0 | 0 | 25 |
| Hypotensive | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| ABO | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| TAD | 7 | 0 | 0 | 0 | 0 | 0 | 0 | 7 |
| Other | 4 | 1 | 0 | 0 | 0 | 0 | 0 | 5 |
| **Total** | **415** | **167** | **69** | **12** | **4** | **5** | **3** | **675** |
| **Percent** | **61.5%** | **24.7%** | **10.2%** | **1.8%** | **0.6%** | **0.7%** | **0.4%** | **100%** |

**Table 8** shows that 8% (54) more adverse events were reported for males than females for most types of adverse events except DSTR.

**Table 8: All adverse events by sex, 2019-20**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Adverse event** | **Male** | **Female** | **Not reported** | **Total** |
| FNHTR | 113 | 93 | 16 | 222 |
| Allergic | 107 | 89 | 45 | 241 |
| TACO | 30 | 24 | 6 | 60 |
| IBCT | 12 | 7 | 12 | 31 |
| Anaphylactic | 14 | 10 | 0 | 24 |
| DHTR | 9 | 9 | 0 | 18 |
| AHTR | 15 | 7 | 2 | 24 |
| TTI | 5 | 5 | 2 | 12 |
| TRALI | 1 | 0 | 1 | 2 |
| DSTR | 8 | 17 | 0 | 25 |
| Hypotensive | 0 | 1 | 2 | 3 |
| ABO | 1 | 0 | 0 | 1 |
| TAD | 4 | 2 | 1 | 7 |
| Other | 2 | 3 | 0 | 5 |
| **Total** | **321** | **267** | **87** | **675** |
| **Percent** | **47.6%** | **39.6%** | **12.9%** | **100%** |

**Table 9** shows more reported adverse events in males than females in the older age groups and the under 5 age group. Females had more reported adverse events than males in the age groups between 25 and 54.

**Table 9: All adverse events by age and sex, 2019-20**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Adverse event** | **Male** | **Female** | **Not reported** | **Total** |
| 0–4 years | 12 | 6 | 4 | 22 |
| 5–14 years | 12 | 13 | 3 | 28 |
| 15–24 years | 14 | 9 | 2 | 25 |
| 25–34 years | 16 | 19 | 12 | 47 |
| 35–44 years | 12 | 18 | 7 | 37 |
| 45–54 years | 32 | 36 | 7 | 75 |
| 55–64 years | 49 | 32 | 12 | 93 |
| 65–74 years | 61 | 59 | 14 | 134 |
| 75 years or older | 105 | 72 | 22 | 199 |
| Not stated | 8 | 3 | 4 | 15 |
| **Total** | **321** | **267** | **87** | **675** |
| **Percent** | **47.6%** | **39.6%** | **12.9%** | **100%** |

Adverse events reported by day and time and remoteness area are shown in **Table 10** and **Table 11.**

**Table 10: All adverse events by time and weekday and remoteness area, 2019-20**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Weekday** | | | | | | | | | | | | |
|  | **Between 7am and 7pm** | | | | | **Between 7pm and 7am** | | | | **Unknown** | | |  |
|  | **Major City** | **Inner Regional** | **Outer Regional** | **Remote** | **Total 7am to 7pm** | **Major City** | **Inner Regional** | **Outer Regional** | **Total 7pm to 7am** | **Major City** | **Inner Regional** | **Total Unknown** | **Total Weekday** |
| FNHTR | 53 | 7 | 19 | 0 | 79 | 57 | 7 | 26 | 90 | 2 | 1 | 3 | 172 |
| Allergic | 99 | 9 | 7 | 0 | 115 | 57 | 4 | 14 | 75 | 4 | 0 | 4 | 194 |
| TACO | 21 | 5 | 0 | 1 | 27 | 21 | 0 | 3 | 24 | 1 | 0 | 1 | 52 |
| IBCT | 6 | 3 | 0 | 0 | 9 | 10 | 3 | 0 | 13 | 1 | 0 | 1 | 23 |
| Anaphylactic | 13 | 3 | 0 | 0 | 16 | 4 | 0 | 0 | 4 | 0 | 0 | 0 | 20 |
| DHTR | 3 | 1 | 2 | 0 | 6 | 6 | 0 | 2 | 8 | 1 | 0 | 1 | 15 |
| AHTR | 11 | 2 | 2 | 0 | 15 | 2 | 1 | 1 | 4 | 1 | 0 | 1 | 20 |
| TTI | 1 | 1 | 0 | 0 | 2 | 2 | 0 | 3 | 5 | 0 | 0 | 0 | 7 |
| TRALI | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| DSTR | 6 | 0 | 0 | 0 | 6 | 12 | 0 | 0 | 12 | 1 | 0 | 1 | 19 |
| Hypotensive | 1 | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 2 | 0 | 0 | 0 | 3 |
| ABO | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |  | 0 | 0 | 0 | 1 |
| TAD | 0 | 1 | 0 | 0 | 1 | 3 | 0 | 0 | 3 | 0 | 0 | 0 | 4 |
| Other | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 2 |
| **Total** | **216** | **32** | **30** | **1** | **279** | **177** | **16** | **49** | **242** | **11** | **1** | **12** | **533** |

**Table 11: All adverse events by time and weekend and remoteness area, 2019-20**

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Weekend** | | | | | | | | | | |  |
|  | **Between 7am and 7pm** | | | | **Between 7pm and 7am** | | | | **Unknown** | |  |  |
|  | **Major City** | **Inner Regional** | **Outer Regional** | **Total 7am to 7pm** | **Major City** | **Inner Regional** | **Outer Regional** | **Total 7pm to 7am** | **Major City** | **Total Unknown** | **Total Weekend** | **Total All** |
| FNHTR | 14 | 2 | 8 | 24 | 15 | 2 | 8 | 25 | 1 | 1 | 50 | 222 |
| Allergic | 21 | 1 | 3 | 25 | 14 | 2 | 5 | 21 | 1 | 1 | 47 | 241 |
| TACO | 1 | 0 | 0 | 1 | 6 | 0 | 1 | 7 | 0 | 0 | 8 | 60 |
| IBCT | 3 | 1 | 0 | 4 | 3 | 1 | 0 | 4 | 0 | 0 | 8 | 31 |
| Anaphylactic | 2 | 0 | 1 | 3 | 0 | 0 | 1 | 1 | 0 | 0 | 4 | 24 |
| DHTR | 1 | 0 | 0 | 1 | 2 | 0 | 0 | 2 | 0 | 0 | 3 | 18 |
| AHTR | 3 | 0 | 0 | 3 | 0 | 0 | 1 | 1 | 0 | 0 | 4 | 24 |
| TTI | 1 | 0 | 0 | 1 | 0 | 0 | 2 | 2 | 2 | 2 | 5 | 12 |
| TRALI | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 2 |
| DSTR | 0 | 0 | 0 | 0 | 6 | 0 | 0 | 6 | 0 | 0 | 6 | 25 |
| Hypotensive | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| ABO | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| TAD | 2 | 0 | 0 | 2 | 1 | 0 | 0 | 1 | 0 | 0 | 3 | 7 |
| Other | 1 | 1 | 0 | 2 | 0 | 1 | 0 | 1 | 0 | 0 | 3 | 5 |
| **Total** | **49** | **5** | **12** | **66** | **48** | **6** | **18** | **72** | **4** | **4** | **142** | **675** |

### Contributory factors for all adverse events, 2015-16 to 2019-20

States and territories report data on factors contributing to each adverse event where applicable.

**Table 12** shows that:

* the most frequent contributory factors reported are ‘None identified’ and ‘Product characteristic’
* ‘Administration of product’ factor reported increased five-fold, from 10 in 2018-19 to 64 in 2019-20.

**Table 12: Contributory factors for all adverse events, 2015-16 to 2019-20**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Summary Data** | **2015-16** | **2016-17** | **2017-18** | **2018-19** | **2019-20** | **% Change from 2018-19** |
| None identified | 286 | 256 | 171 | 245 | 330 | 34.7% |
| Product characteristic | 360 | 319 | 193 | 182 | 174 | -4.4% |
| Transfusion in emergency setting | 17 | 11 | 13 | 19 | 24 | 26.3% |
| Deliberate clinical decision | 36 | 33 | 29 | 40 | 46 | 15.0% |
| Prescribing/ordering | 15 | 18 | 12 | 5 | 5 | 0.0% |
| Specimen collection/labelling | 0 | 0 | 1 | 3 | 2 | -33.3% |
| Laboratory (testing/dispensing) | 23 | 11 | 13 | 9 | 16 | 77.8% |
| Transport, storage, handling | 1 | 1 | 1 | 1 | 1 | 0.0% |
| Administration of product | 15 | 18 | 42 | 10 | 64 | 540.0% |
| Indications do not meet guidelines | 2 | 9 | 8 | 5 | 6 | 20.0% |
| Procedure did not adhere to hospital transfusion guidelines | 15 | 18 | 19 | 9 | 7 | -22.2% |
| Other | 20 | 58 | 53 | 48 | 81 | 68.8% |

### Contributory factors for all adverse events for 2019-20

**Table 13** shows a breakdown of reported contributory factors by adverse event and outcome severity for 2019-20.

* ‘Administration of product’ was reported to be associated with FNHTRs and allergic reactions
* ‘Transfusion in emergency setting’ was reported to be associated with IBCTs
* ‘Laboratory (testing/dispensing) was also reported to be associated with IBCTs (12), with two life-threatening cases in 2019-20.

**Table 13: Contributory factors by adverse event and by clinical outcome severity, 2019-20**



**Note: One adverse event can be associated with more than one contributory factor**

### Classification of adverse events

The NBA classified all adverse events into three categories based on outcome severity and imputability ratings shown in **Table 14** as follows.

**Non-transfusion related adverse event (AE):** A non-transfusion related adverse event is an event classified as ‘excluded or unlikely’, ‘not assessable’ to be related to blood transfusion regardless of outcome severity rating.

**Transfusion-related non-serious adverse event (non-SAE)**: A transfusion-related non-serious adverse event is an event classified as ‘possible’, ‘likely/probable ‘or ‘confirmed/certain’ to be related to blood transfusion and results in ‘outcome not available’ or ‘no morbidity’ or ‘minor morbidity’ to a patient.

**Transfusion-related serious adverse event (SAE)**: A transfusion related serious adverse event is an event classified as ‘possible’, ‘likely/probable’ or ‘confirmed/certain’ to be related to blood transfusion and results in ‘severe morbidity’ or a ‘life-threatening’ or ‘death’ to a patient.

**Table 14: Adverse event groups based on imputability score and outcome severity**

|  |  |  |
| --- | --- | --- |
| **Outcome severity** | **Imputability score** | |
|  | **Excluded or Unlikely / Not Assessable** | **Definite (certain) / Probable (likely) / Possible** |
| **Death** | **Non-transfusion related AE** | **Transfusion-related SAE** |
| **Life-threatening** |
| **Severe morbidity** |
| **Minor morbidity** | **Transfusion-related non-SAE** |
| **No morbidity** |
| **Outcome not available** |

**Table 15** shows reported adverse events reclassified as per the rules defined above and the highlights are:

* most reports (75.7% or 2,282) are transfusion-related non-SAEs
* transfusion-related SAEs reported represented 10.8% (326)
* 13.5% (407) of all reports are non-transfusion related AEs.

**Table 15: Adverse events by event group, 2015-16 to 2019-20**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Adverse event group** | **2015-16** | **2016-17** | **2017-18** | **2018-19** | **2019-20** | **Total** | **% of 2019-20** |
| Non-transfusion related AE | 77 | 90 | 93 | 61 | 86 | 407 | **12.7%** |
| Transfusion-related non-SAE | 598 | 451 | 330 | 385 | 518 | 2,282 | **76.7%** |
| Transfusion-related SAE | 49 | 87 | 65 | 54 | 71 | 326 | **10.5%** |
| **Total** | **724** | **628** | **488** | **500** | **675** | **3,015** | **100%** |

**Table 16** shows non-transfusion related AEs by state from 2015-16 to 2019-20. The Victorian Blood Matters Serious Transfusion Incident Reporting (STIR) for participating states (VIC, TAS, NT and ACT), reports serious adverse events and excludes non-transfusion related adverse events, while QLD has included the non-transfusion related adverse events.

**Table 16: Non-transfusion related AEs by state, 2015-16 to 2019-20**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | **2015-16** | **2016-17** | **2017-18** | **2018-19** | **2019-20** | **Total** | **% of 2019-20** |
| NSW | 12 | 12 | 2 | 3 | 17 | 46 | **19.8%** |
| VIC | 1 | 0 | 1 | 3 | 2 | 7 | **2.3%** |
| QLD | 41 | 65 | 45 | 39 | 55 | 245 | **64.0%** |
| SA | 18 | 9 | 35 | 7 | 5 | 74 | **5.8%** |
| WA | 5 | 3 | 9 | 9 | 6 | 32 | **7.0%** |
| TAS | 0 | 0 | 0 | 0 | 0 | 0 | **0.0%** |
| NT | 0 | 0 | 0 | 0 | 0 | 0 | **0.0%** |
| ACT | 0 | 1 | 1 | 0 | 1 | 3 | **1.2%** |
| **Total** | **77** | **90** | **93** | **61** | **86** | **407** | **100%** |

**Table 17** shows that QLD reported the largest percentage of transfusion-related non-SAEs (39.3% or 897) over the past five years, followed by NSW (26.4% or 602) and WA (13.7% or 312).

**Table 17: Transfusion-related non-SAEs by state, 2015-16 to 2019-20**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | **2015-16** | **2016-17** | **2017-18** | **2018-19** | **2019-20** | **Total** | **% of 2019-20** |
| NSW | 263 | 149 | 45 | 61 | 84 | 602 | **16.2%** |
| VIC | 41 | 37 | 34 | 31 | 68 | 211 | **13.1%** |
| QLD | 189 | 157 | 143 | 183 | 225 | 897 | **43.4%** |
| SA | 37 | 37 | 25 | 43 | 62 | 204 | **12.0%** |
| WA | 64 | 61 | 67 | 53 | 67 | 312 | **12.9%** |
| TAS | 0 | 4 | 10 | 0 | 4 | 18 | **0.8%** |
| NT | 3 | 5 | 0 | 12 | 5 | 25 | **1.0%** |
| ACT | 1 | 1 | 6 | 2 | 3 | 13 | **0.6%** |
| **Total** | **598** | **451** | **330** | **385** | **518** | **2,282** | **100%** |

**Table 18** shows that VIC reported the largest percentage of transfusion-related SAEs (35.3% or 115) over the past five years due to only collecting serious adverse events for national reporting, followed by QLD (27.0% or 88) and NSW (16.3% or 53).


**Table 18: Transfusion-related SAEs by state, 2015-16 to 2019-20**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | **2015-16** | **2016-17** | **2017-18** | **2018-19** | **2019-20** | **Total** | **% of 2019-20** |
| NSW | 6 | 14 | 14 | 8 | 11 | 53 | **15.5%** |
| VIC | 12 | 32 | 22 | 24 | 25 | 115 | **35.2%** |
| QLD | 20 | 24 | 14 | 11 | 19 | 88 | **26.8%** |
| SA | 7 | 8 | 1 | 2 | 2 | 20 | **2.8%** |
| WA | 4 | 7 | 9 | 6 | 10 | 36 | **14.1%** |
| TAS | 0 | 1 | 1 | 0 | 2 | 4 | **2.8%** |
| NT | 0 | 0 | 2 | 0 | 0 | 2 | **0.0%** |
| ACT | 0 | 1 | 2 | 3 | 2 | 8 | **2.8%** |
| **Total** | **49** | **87** | **65** | **54** | **71** | **326** | **100%** |

### Hospital participation in haemovigilance reporting

States and territories reported the hospital participation data in **Figure 1** for 2019-20:

* 495 hospitals participated in the national haemovigilance reporting, including 420 public hospitals and 75 private hospitals
* 26.3% (130) participating hospitals reported adverse events, including 106 public hospitals and   
  24 private hospitals
* QLD had the highest number of reporting hospitals for both public and private and the highest number of participating hospitals for private
* private hospitals from NSW, SA and NT didn’t participate in the national haemovigilance reporting
* only three states (VIC, QLD and WA) reported adverse events for private hospitals



**Figure 1: Number of participating and reporting hospitals by public/private and state, 2019-20**

**Table 19** shows the number of participating hospitals reported adverse events by state and public/private.

**Table 19: Number of participating and reporting hospitals by public/private and state, 2019-20**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **NSW** | **VIC** | **QLD** | **SA** | **WA** | **TAS** | **NT** | ACT |
| **Participating hospitals** | Public | 172 | 61 | 80 | 43 | 53 | 4 | 5 | 2 |
| Private | 0 | 25 | 30 | 0 | 12 | 5 | 0 | 3 |
| **Reporting hospitals** | Public | 37 | 20 | 23 | 10 | 11 | 2 | 2 | 1 |
| Private | 0 | 4 | 16 | 0 | 4 | 0 | 0 | 0 |

Nationally, 5.2 adverse events per hospital were reported for 2019-20. This varied between states and territories, ranging from 2.5 in NT to 7.7 in QLD. A breakdown of adverse events by three classifications shows the following key results as shown in **Table 20.**

* QLD reported the highest rate of non-transfusion related AEs per hospital at 1.4, followed by ACT at 1.0
* SA reported the highest rate of transfusion-related non-SAE per hospital at 6.2, followed by QLD at 5.8
* noting that only serious AEs are collected and reported by the STIR, those participating states and territories except NT reported a higher rate of transfusion-related SAEs per hospital than other states and territories, with ACT at 2.0, VIC at 1.0 and TAS at 1.0

**Table 20: Number of adverse events per hospital by state, 2019-20**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **NSW** | **VIC** | **QLD** | **SA** | **WA** | **TAS** | **NT** | **ACT** | **Total** |
| **Number of reporting hospitals** | **37** | **24** | **39** | **10** | **15** | **2** | **2** | **1** | **130** |
| **Number of adverse events** | **112** | **95** | **299** | **69** | **83** | **6** | **5** | **6** | **675** |
| Non-transfusion related AE | 17 | 2 | 55 | 5 | 6 | 0 | 0 | 1 | 86 |
| Transfusion-related non-SAE | 84 | 68 | 225 | 62 | 67 | 4 | 5 | 3 | 518 |
| Transfusion-related SAE | 11 | 25 | 19 | 2 | 10 | 2 | 0 | 2 | 71 |
| **Adverse events per hospital** | **3.0** | **4.0** | **7.7** | **6.9** | **5.5** | **3.0** | **2.5** | **6.0** | **5.2** |
| Non-transfusion related AE | 0.5 | 0.1 | 1.4 | 0.5 | 0.4 | 0.0 | 0.0 | 1.0 | 0.7 |
| Transfusion-related non-SAE | 2.3 | 2.8 | 5.8 | 6.2 | 4.5 | 2.0 | 2.5 | 3.0 | 4.0 |
| Transfusion-related SAE | 0.3 | 1.0 | 0.5 | 0.2 | 0.7 | 1.0 | 0.0 | 2.0 | 0.5 |

### 2015-16 to 2019-20 reclassified

This section presents the reclassified adverse event data and key results for 2015-16 to 2019‑20.

**Table 21** and **Table 22** show that FNHTR contributed to the highest number of non-transfusion related AEs (62.9%) and transfusion-related non-SAEs (42.4%), followed by allergic reactions with 14.0% for non-transfusion related AEs and 33.4% for transfusion related non-SAEs.

**Table 21: Non-transfusion related AEs, 2015-16 to 2019-20**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Adverse event** | **2015-16** | **2016-17** | **2017-18** | **2018-19** | **2019-20** | **All reports** | |
|  |  |  |  |  |  | **Total** | **Percent** |
| FNHTR | 50 | 65 | 47 | 36 | 58 | 256 | 62.9% |
| Allergic | 11 | 13 | 15 | 13 | 5 | 57 | 14.0% |
| TACO | 2 | 6 | 6 | 2 | 5 | 21 | 5.2% |
| IBCT | 6 | 1 | 2 | 5 | 5 | 19 | 4.7% |
| Anaphylactic | 2 | 1 | 0 | 0 | 0 | 3 | 0.7% |
| DHTR | 0 | 2 | 2 | 0 | 0 | 4 | 1.0% |
| AHTR | 1 | 0 | 3 | 2 | 4 | 10 | 2.5% |
| TTI | 4 | 0 | 4 | 0 | 6 | 14 | 3.4% |
| TRALI | 1 | 2 | 1 | 1 | 0 | 5 | 1.2% |
| DSTR | 0 | 0 | 1 | 1 | 0 | 2 | 0.5% |
| Hypotensive | 0 | 0 | 5 | 0 | 1 | 6 | 1.5% |
| TAD | 0 | 0 | 0 | 0 | 2 | 2 | 0.5% |
| Other | 0 | 0 | 7 | 1 | 0 | 8 | 2.0% |
| **Total** | **77** | **90** | **93** | **61** | **86** | **407** | **100%** |

**Table 22: Transfusion-related non-SAEs, 2015-16 to 2019-20**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | **2015-16** | **2016-17** | **2017-18** | **2018-19** | **2019-20** | **All reports** | |
|  |  |  |  |  |  | **Total** | **Percent** |
| FNHTR | 309 | 219 | 152 | 131 | 156 | 967 | 42.4% |
| Allergic | 167 | 129 | 85 | 159 | 222 | 762 | 33.4% |
| TACO | 37 | 30 | 30 | 19 | 37 | 153 | 6.7% |
| IBCT | 34 | 18 | 21 | 6 | 23 | 102 | 4.5% |
| Anaphylactic | 15 | 25 | 2 | 11 | 7 | 60 | 2.6% |
| DHTR | 16 | 18 | 11 | 14 | 17 | 76 | 3.3% |
| AHTR | 7 | 9 | 4 | 13 | 16 | 49 | 2.1% |
| TTI | 13 | 1 | 8 | 2 | 3 | 27 | 1.2% |
| TRALI | 0 | 2 | 0 | 0 | 0 | 2 | 0.1% |
| PTP | 0 | 0 | 1 | 1 | 0 | 2 | 0.1% |
| DSTR | NA | NA | 9 | 15 | 25 | 49 | 2.1% |
| Hypotensive | NA | NA | 1 | 4 | 2 | 7 | 0.3% |
| ABO | NA | NA | 1 | 0 | 1 | 2 | 0.1% |
| TAD | NA | NA | 0 | 7 | 4 | 11 | 0.5% |
| Other | NA | NA | 5 | 3 | 5 | 13 | 0.6% |
| **Total** | **598** | **451** | **330** | **385** | **518** | **2,282** | **100%** |

**Table 23** shows that 326 transfusion-related SAEs of 12 different types were reported to the national haemovigilance program. TACO and anaphylactic reactions related to 82.5% of reported SAEs. Allergic reactions and FNHTRs accounted for 17.8% and 14.4% SAEs respectively.

**Table 23: Transfusion-related SAEs, 2015-16 to 2019-20**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | **2015-16** | **2016-17** | **2017-18** | **2018-19** | **2019-20** | **All reports** | |
|  |  |  |  |  |  | **Total** | **Percent** |
| FNHTR | 6 | 20 | 11 | 2 | 8 | 47 | 14.4% |
| Allergic | 15 | 15 | 7 | 7 | 14 | 58 | 17.8% |
| TACO | 12 | 19 | 16 | 21 | 18 | 86 | 26.4% |
| IBCT | 1 | 1 | 0 | 0 | 3 | 5 | 1.5% |
| Anaphylactic | 13 | 19 | 18 | 18 | 17 | 85 | 26.1% |
| DHTR | 0 | 1 | 6 | 1 | 1 | 9 | 2.8% |
| AHTR | 1 | 4 | 1 | 0 | 4 | 10 | 3.1% |
| TTI | 0 | 0 | 3 | 1 | 3 | 7 | 2.1% |
| TRALI | 1 | 8 | 2 | 0 | 2 | 13 | 4.0% |
| ABO | NA | NA | 1 | 1 | 0 | 2 | 0.6% |
| TAD | NA | NA | 0 | 0 | 1 | 1 | 0.3% |
| Other | NA | NA | 0 | 3 | 0 | 3 | 0.9% |
| **Total** | **49** | **87** | **65** | **54** | **71** | **326** | **100%** |

**Table 24** shows a breakdown of non-transfusion related AEs by imputability score and outcome.

* 6 in 10 non-transfusion related AEs are FNHTRs
* most non-transfusion related AEs were reported to cause either no morbidity (126 out of 407) or only minor morbidity outcomes (207 out of 407)
* two deaths, 4 life-threatening cases and 36 severity morbidity cases are not reported to be related to transfusion. These events should be excluded from analysis.

**Table 24: Non-transfusion related AEs by imputablity score and outcome severity, 2015-16 to 2019-20**



**Table 25** shows a breakdown of non-SAEs by imputability score and outcome severity.

* 30% (522) of non-SAEs caused no harm to patients
* 73% (1,670) of non-SAEs were reported to be related to minor morbidities to patients
* 33% (758) of non-SAEs were reported to be possibility related to blood transfusion32% (736) of non-SAEs were reported to be likely related to blood transfusion.

**Table 25: Transfusion-related non-SAEs by imputablity score and outcome severity, 2015-16 to 2019-20**



**Table 26** shows abreakdown of SAEs by imputability score and outcome severity.

* Four reported deaths were possibly or likely to be related to transfusion, with two anaphylactic reactions, one Transfusion-related acute lung injury (TRALI) and one ABO incompatibility
* 40% of reported SAEs (131 out of 326) were life-threatening
* 59% of SAEs (191 out of 326) were reported to be related to severe morbidity, including 53 TACOs, 44 FNHTRs and 38 allergic reactions.

**Table 26: Transfusion-related SAEs by imputablity score and outcome severity, 2015-16 to 2019-20**



### Recommendations

This report makes six recommendations in four areas based on the NBA’s 2018-21 Haemovigilance Work Plan. The NBA and the HAC have set up working groups to implement the first five recommendations

#### Guideline development

1. Publish the revised AHMDS.
2. Publish the Guidance on Investigation and Management of Acute Transfusion Reactions.

#### National tools and resources

1. Develop case studies for identified clinical priorities.
2. Update the haemovigilance reporting forms in line with the new version of AHMDS when released.

#### Education and training

1. Identify training needs for haemovigilance.

#### Research and development

1. Include haemovigilance as a future topic in the National Blood Sector Research and Development Program.

# **SECTION 2**

**Lifeblood**

## **Donor Vigilance Report 2019-2020**

30 November 2020

**Australian Red Cross Lifeblood** │Donor Vigilance Report 2018-2019

# Introduction

Whilst blood donation is generally a safe process, there are recognised complications which can occur. Lifeblood’s donor vigilance system monitors adverse events in blood donors that have a temporal relationship to blood donation. The system underpins Lifeblood’s comprehensive and continuous improvement approach to the mitigation and management of donor adverse events to improve donor safety, experience and retention and is integral to Lifeblood’s Clinical and Quality Governance Framework. This report provides a national overview of the donor adverse event rates by donation category for the 2019‑20 financial year (FY) along with comparative data from the three previous years.

# Reporting parameters

## **Donation categories**

Lifeblood collects both whole blood and specific blood components (plasma and platelets). The donor’s suitability for a donation type is assessed prior to each donation.

A whole blood donation involves the collection of approximately 500mL of blood which takes an average of 8‑9 minutes1[[1]](#footnote-1) from when the needle is inserted. This donation process does not involve the return of any blood components back to the donor.

The donation of plasma and/or platelet components is by apheresis and involves the use of an automated machine that separates whole blood into cellular components and plasma. The machine draws blood from the donor and mixes it with anticoagulant (citrate) solution to prevent clotting. It then separates out the plasma and/or platelets and returns the remainder of the blood (which includes the donor’s red cells), along with a small amount of anticoagulant solution, to the donor. This cycle is repeated until the target collection volume is reached. Plasmapheresis is associated with larger collection volumes than plateletpheresis and as an additional safety measure, plasmapheresis donors receive 500mL of saline solution through the donation needle at the middle and/or end of the donation. Lifeblood commenced the roll-out of a new plasmapheresis platform in May 2019; almost all centres had transitioned to the new platform by June 2020. Plasmapheresis donors using the new plasmapheresis platform only receive saline at the end of the donation. A plasmapheresis donation takes an average of approximately 41 minutes[[2]](#footnote-2) and a plateletpheresis donation, 72 minutes[[3]](#footnote-3). Since 2015-16, plateletpheresis donations have been predominantly collected from male donors as a risk mitigation strategy for transfusion-related acute lung injury (TRALI).

By virtue of the collection process, the adverse event profile is quite different for the different donation types. Comparisons across donation types can be valuable but must also be considered in the context of the different processes for each collection type and differing donor demographics and donor experience. For instance, the higher rate of phlebotomy-related events in apheresis compared with whole blood relates to the longer collection time, the nature of the draw and return cycles including the return of red cells and delivery of saline solution and the use of anticoagulant. The higher rate of citrate reactions and haematomas in plateletpheresis compared with plasmapheresis is related to the higher rate of citrate delivery and longer procedure.

## **Denominator cohort and rates**

The denominator cohort used to calculate donor adverse event rates were those attendances that progressed to a donation attempt and have a needle inserted, regardless of whether the target collection volume was achieved. Definitions for new and returning donors are provided in the Glossary (Appendix 1). Adverse event rates have been calculated per 10,000 donation attempts. Rates for total donor adverse events will only count a donation once even if the donation was associated with more than one type of adverse event or multiple events of the same type. As such the total donor adverse rate will be lower than the sum of individual reaction rates.

## **Donor adverse events**

Donor adverse events (DAE) are recorded in Lifeblood’s Incident and Quality DAE module. The 2019-20 FY data includes events registered by 31 July 2020. Donor adverse events are categorised into the following four categories:

#### Vasovagal reactions:

Donors may feel faint and experience symptoms such as dizziness, light-headedness and nausea. In some cases, the donor may faint (lose consciousness). These symptoms may be triggered by anxiety or pain and/or occur as a result of the reduction in blood volume. In many cases when donors feel faint or faint, there are multiple contributing factors.

#### Phlebotomy related injury:

These refer to complications arising from having a needle inserted. These include bleeding or bruising (haematoma) which may result from incorrect placement or dislodgment of the needle from the vein, piercing of an artery (arterial puncture), irritation or damage to a nerve (nerve injury), infection (cellulitis) or inflammation (phlebitis) which may be associated with clot formation (thrombophlebitis).

#### Apheresis specific events:

These events relate to exposure to citrate, the return of red cells, the administration of saline solution and apheresis machine/process issues. Citrate binds calcium temporarily reducing calcium levels in the blood which can cause symptoms such as tingling around the mouth, a metallic taste in the mouth or altered sensation of hands and feet. Leakage of blood and/or saline solution into the tissues may occur during a return cycle (infiltration/extravasation) and lead to swelling and bruising in the arm and in very rare circumstances compartment syndrome. A machine or process issue can result in damage to the donor’s red cells (haemolysis), insufficient administration of anticoagulant or air entering the line. If undetected and cells are returned to the donor, this may lead to a donor adverse event.

#### Other category:

This captures all other events that occur within 24 hours of the donation including allergic reactions, chest pain and major thrombotic events. An assessment is made as to the imputability of the donation as the cause.

# Results

## **Donations in the reporting period**

The number of donations meeting inclusion criteria for the reporting period for FY 2016-17 to 2019-20 are provided in **Table 1a**. In 2019-20 there was a 10% increase in plasmapheresis donations and a negligible reduction in whole blood and plateletpheresis.

Table 1b. provides an overview of donor demographics for 2019-20 and the change from 2018-19. In 2019‑20, both whole blood and plasmapheresis had a significantly higher proportion of donations from females compared with 2018-19. The whole blood cohort also had a significantly higher proportion of donations from new female and male donors and males aged less than 30. In contrast, the plasma cohort had significantly lower proportion of donations from both new male and female donors and donors aged less than 30.

Table 1a: Number of donations in the denominator cohort for FY 2016-17 to 2019-20

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Donation Type** | **2016-17** | **2017-18** | | **2018-19** | | **2019-20** | |
| **Whole Blood** | 712,808 | 700,546 | | 703,986 | | 701,475 | |
| **Plasmapheresis** | 579,178 | 646,488 | | 745,666 | | 822,903 | |
| **Plateletpheresis** | 32,337 | 27,782 | | 29,127 | | 27, 501 | |
| **Total** | **1,324,323** | **1,374,816** | **1,478,779** | | **1,551,879** | |

Table 1b: Donor demographics by donation category for FY 2019-20 and change from 2018-19

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Donation**  **Type** | **Number of Donations**  **(% change)** | **% of Total Donations for the year** | **Females** | | | | **Males** | | | | | |
| **% of**  **Donations** | **Mean age in years (change)** | **% <30 years** | **% new donors** | **% of donations** | **Mean age in years (change)** | | **% <30 years** | | **% of new donors** |
|  | | | |  | | | | | |
| **Whole**  **Blood** | 701,475  (-0.36%) | 45.20 | 49.99  (+0.59)^ | 42.02  (-0.15) | 27.89  (-0.2) *#* | 20.84  (+1.15)^ | 50.01  (-0.59) | 45.68  (-0.87) | 18.49  (+0.22)^ | | 15.18  (+1.08)^ | |
| **Plasma** | 822,903  (+10.36%) | 53.03 | 42.90  (+0.83)^ | 42.98  (+0.01) | 26.78  (-0.24)^ | 11.03  (-1.07)^ | 57.10  (-0.83) | 46.22  (+0.10) | 18.51  (-0.75)^ | | 6.46  (-0.47)^ | |
| **Platelets** | 27, 501  (-5.58%) | 1.77 | 0.27  (-0.23) | 53.28  (+1.69) |  |  | 99.73  (+0.23) | 45.16  (+0.08) | 17.68  (-1.02)^ | |  | |
| **Total** | 1,551,879  (+4.94%) | 100.00 | 45.35  (+0.61) | 42.50  (-0.05) |  |  | 54.65  (-0.61) | 45.96  (-0.08) |  | |  | |

*^p<0.05*  *#p>0.05*  (Chi-squared p values)

## **Donor adverse events by donation category**

Total donor adverse event rates per 10,000 donations by donation type from 2016-17 to 2019-20 are provided in Table 2a. Tables 2b and 2c provide rates for individual events for 2019-20. The total rate for the year will only include a donation once even if more than one event was reported in association with that donation. The total rates in Table 2a for 2019-20 are therefore less than the sum of individual rates provided in Tables 2b and 2c.

Table 2a: Total donor adverse event rates per 10,000 donations for FY 2016-17 to 2019-20

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Total adverse event rate per 10,000 donations**  **(rate change from previous year)** | | | | | | | **Comparison of FY 19-20 with 18-19**  **Relative Risk (95% Confidence Interval; p value)** |
| **Donation Type** | **2016-17** | | **2017-18** | | **2018-19** | | **2019-20** | **Number of donations for one additional event** |
| **Whole Blood** | 310.57 | | 299.05 | | 297.09 | | 321.76 | 1.08 (1.06-1.10; p<0.001) |
|  | (-6.51) | | (-11.52) | | (-1.96) | | (+24.67) | 406 |
| **Plasmapheresis** | 188.89 | | 261.60 | | 324.13 | | 455.08 | 1.40 (1.38-1.43; <0.001) |
|  | (-10.20) | | (+72.71) | | (+62.53) | | (+130.95) | 77 |
| **Plateletpheresis** | 753.63 | | 976.17 | | 1,047.14 | | 990.15 | 0.95 (0.90-0.99; p=0.03) |
|  | (-49.02) | | (+222.54) | | (+70.97) | | (-56.99) | -176 |
| **Total** | 268.17 | | 295.12 | | 325.50 | | 404.30 | 1.24 (1.23-1.26; p<0.001) |
|  | (-10.89) | (+26.95) | | (+30.38) | | (+78.80) | | 127 |

Table 2b: Donor adverse event rates per 10,000 donations by donation type for 2019-20 and rate change from 2018-19

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Whole Blood n=701,475** | | | **Plasmapheresis n=822,903** | | | **Plateletpheresis n=27,501** | | | **Total n=1,551,879** | |
| **Event type** | **Event (n)** | **Rate**  **(change)** | **Event (n)** | **Rate**  **(change)** | **Event (n)** | | **Rate**  **(change)** | | **Event (n)** | **Rate**  **(change)** |
| **Vasovagal events** | 15,785 | 225.03  (+14.44) | 9,661 | 117.40  (-6.02) | 352 | | 128.00  (-5.55) | 25,798 | | 166.24  (+1.12) |
| **Phlebotomy Related** |  |  |  |  |  | |  |  | |  |
| Arterial Puncture | 31 | 0.44  (+0.10) | 21 | 0.26  (+0.02) | 0 | | 0.00  (0.00) | 52 | | 0.34  (+0.06) |
| Cellulitis | 4 | 0.06  (-0.04) | 4 | 0.05  (+0.01) | 1 | | 0.36  (+0.36) | 9 | | 0.06  (-0.01) |
| Delayed Bleeding | 143 | 2.04  (+0.16) | 645 | 7.84  (+0.87) | 7 | | 2.55  (+0.83) | 795 | | 5.12  (+0.68) |
| Haematoma | 4,533 | 64.62  (+7.43) | 13,380 | 162.60  (+62.33) | 1,080 | | 392.71  (+1.32) | 18,993 | | 122.39  (+36.89) |
| Nerve Injury/Irritation | 668 | 9.52  (+1.88) | 961 | 11.68  (+4.46) | 18 | | 6.55  (+0.71) | 1,647 | | 10.61  (+3.22) |
| Other injury | 36 | 0.51  (-0.04) | 72 | 0.87  (-0.19) | 4 | | 1.45  (-0.95) | 112 | | 0.72  (-0.13) |
| Painful arm^ | 1,785 | 25.45  (+5.07) | 5,235 | 63.62  (+28.86) | 190 | | 69.09  (+20.68) | 7,210 | | 46.46  (+18.27) |
| Thrombophlebitis | 19 | 0.27  (-0.04) | 32 | 0.39  (+0.01) | 2 | | 0.73  (+0.39) | 53 | | 0.34  (0.00) |
| **Other Event Type** |  |  |  |  |  | |  |  | |  |
| Anaphylaxis | 0 | 0.00  (-0.03) | 2 | 0.02  (+0.01) | 0 | | 0.00  (0.00) | 2 | | 0.01  (-0.01) |
| Chest Pain | 36 | 0.51  (-0.12) | 68 | 0.83  (0.00) | 0 | | 0.00  (-0.69) | 104 | | 0.67  (-0.06) |
| Local Allergic Reaction | 129 | 1.84  (-3.13) | 223 | 2.71  (-4.09) | 3 | | 1.09  (-2.0) | 355 | | 2.29  (-3.57) |
| Other event/injury | 128 | 1.82  (-0.06) | 205 | 2.49  (-0.31) | 9 | | 3.27  (-1.88) | 342 | | 2.20  (-0.21) |

^ *Rate reflects painful arm when not reported in association with another phlebotomy injury including haematoma*

Table 2c: Specific apheresis-related donor adverse event rates per 10,000 donations for FY 2019-20 and rate change from 2018-19.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Plasmapheresis n=822,903** | | | **Plateletpheresis n=27,501** | | **Total n= 850,404** | |
| **Event type** | **Event (n)** | **Rate**  **(change)** | **Event (n)** | **Rate**  **(change)** | **Event (n)** | **Rate**  **(change)** |
| **Citrate Reaction+** | 7,841 | 95.28  (+37.91) | 1,154 | 419.62  (-102.58) | 8,995 | 105.77  (+30.92) |
| **Haemolysis\*** | 30 | 0.36  (+0.36) | 0 | 0.00  (0.00) | 30 | 0.35  (+0.35) |
| **Infiltration/extravasation** | 2,304 | 28.00  (+20.50) | 107 | 38.91  (+15.22) | 2,411 | 28.35  (+20.24) |
| **Omitted Anticoagulant^** | 0 | 0.00  (0.00) | 0 | 0.00  (0.00) | 0 | 0.00  (0.00) |

*+ Plasma includes 333 moderate and 13 severe cases, Platelets includes 50 moderate and 0 severe cases*

*\* Events with a high index of suspicion that haemolysis occurred and red cells were returned to the donor.*

*^DAE is not reported if the donor remains asymptomatic*

* + 1. **Whole blood**

Total DAE rates for whole blood increased significantly by 8.3% from 297.09 per 10,000 donations in 2018-19 to 321.76 per 10,000 donations in 2019-20 (RR[[4]](#footnote-4):1.08; 95%CI[[5]](#footnote-5): 1.06-1.10; p<0.001). The increase is attributed primarily to the significant increases observed in rates for vasovagal reactions (210.59 to 225.03 per 10,000 donations; RR: 1.07; 95%CI: 1.05-1.09; p<0.001) and haematoma (57.19 to 64.62 to per 10,000 donations; RR: 1.13; 95%CI: 1.08-1.18; p<0.001). In 2019-20 there was an additional vasovagal every 693 whole blood donations and an additional haematoma for every 1,346 donations.

The standardised 2019-20 vasovagal rate adjusting for gender, new donors and donors aged less than 30 years using the 2018-2019 population is 219.21 per 10,000 donations. The differences in demographic and donation experience therefore account for approximately 40% of the difference observed between 2018-19 and 2019-20. The remaining difference is an increase observed in new donors (Refer Table 3a). The increase in reported vasovagal rates in new donors is likely to be multifactorial and may relate in part to reduced compliance with in-centre water loading and applied muscle tensing exercises.

The increase in haematoma events may still relate to the haematoma definition change in September 2017 which introduced the reporting of all haematomas, not just those greater than 5cm. The higher proportion of females and new donors compared with 2018-19 may also be contributory. There has not been an increase in the rates for haematomas requiring external care in 2019-20 compared with 2018-19 (1.14 per 10,000 donations in 2018-19 vs 0.96 per 10,000 donations in 2019-20; RR 0.84; 95%CI: 0.61-1.16; p=0.29), suggesting the increase in reporting relates to more minor events.

* + 1. **Plasmapheresis**

In May 2019 Lifeblood commenced the introduction a new machine for plasmapheresis collection. The new platform collects a smaller extracorporeal volume per cycle than the previous platform, offering potential benefits for both donor experience, including reducing risk of vasovagal reactions, and product quality. At 30 June 2020, almost all centres had transitioned to the new platform. Approximately 58% of plasmapheresis collections in 2019-20 were using the new machines.

The transition to the new machine has been associated with a reduction in vasovagal reactions, from 123.42 in 2018-19 to 117.40 per 10,000 donations (RR: 0.95; 95%CI: 0.92-0.98; p<0.001). There has however been an increase in rates for phlebotomy injuries and infiltration/extravasation events. This includes; an additional haematoma every 161 donations, an additional painful arm (where no other cause identified) every 347 donations, and an additional infiltration/extravasation event every 488 donations. Factors contributing to this may include that the new platform needs more cycles to collect the same plasma volume and in association with this is more sensitive to phlebotomy technique. These rates were monitored closely during 2019-20. A tool-kit of phlebotomy improvement measures were implemented, including a standardised way to secure the venepuncture needle. These initiatives have been associated with a progressive reduction in haematoma and painful arm rates over the course of the reporting year.

An increase in citrate reactions were also observed, noting that 96% of citrate reactions were mild. The increase in citrate reactions may be explained by the citrate being delivered in a smaller volume over a shorter period.

Although there has been an increase in some events, these rates were either similar to or significantly lower than rates observed with plateletpheresis collections. Further, the overall rate of plasmapheresis adverse events requiring external care in 2019-20 (6.44 per 10,000 donations) was not significantly different to the overall 2018‑19 rate (6.84 per 10,000 donations), during which time 95% of collections were on the original platform.

* + 1. **Plateletpheresis**

In general, the donor adverse rate for plateletpheresis has significantly decreased primarily as a result of the decrease in the rate of citrate reactions by 19.64% from 522.20 to 419.62 per 10,000 donations (RR; 0.80; 95% CI: 0.75-0.87; p<0.001), and to a lesser extent the smaller decrease in vasovagal reactions by 4.2% from 133.55 to 128.00 per 10,000 donations (RR: 0.96; 95% CI: 0.83-1.11; p=0.56). These reductions have in part been offset by an increase in the rate for painful arm equating to an extra event every 484 donations. Whilst the underlying causes of these changes are not clear the analysis does not include a subgroup analysis such as age and experience which may account for the changes.

* + 1. All **donation** types

Local skin reaction rates have reduced across all categories and is attributed to a change from antiseptic swabs to antiseptic wipes from early December 2018, after reaction rates of up to 12 per 10,000 were observed in the months of September to November 2018, which were attributed to the particular swab. The overall 2019-20 rate was 2.29 per 10,000, down from 5.86 per 10,000 in the previous year (RR 0.39; 95% CI; 0.35‑0.44; p<0.001).

## **Vasovagal events**

Vasovagal events are the most common donor adverse event if considered across all donation categories. The overall rate of vasovagal events across all donation categories for the FY 2019-20 was 166.24 per 10,000 donations; steady from the previous year rate of 165.12 per 10,000, noting that there has been a reduction in vasovagal rates in apheresis but increases in whole blood.

* + 1. **Age, gender and donor experience**

In keeping with historical trends, in 2019-20 significantly higher rates of vasovagal were observed in new donors compared with returning donors, younger donors compared with older cohorts and females compared with males.

**Donation experience:**

Donors new to a donation type have significantly higher risks of a vasovagal than their returning counterparts. This is in part due to deferral or self-deferral for those who have previously experienced symptoms. Also, returning donors become more familiar with the donation process and mitigation strategies.

**Whole blood**

The relative risk of a new whole blood donor having a vasovagal reaction compared with a returning whole blood donor was 3.81 and 7.42 for females and males respectively (Table 3a). An additional event was reported in a new donor every 19 donations for females and 22 for males. The rates for new male and female whole blood donors were significantly higher in 2019-20 compared with 2018-19. In contrast, there was no difference in rates for returning donors.

**Plasmapheresis**

In 2019-20, the relative risk of a vasovagal in a donor new to plasma compared with a returning plasma donor was 6.00 for females and 12.25 for males (Table 3b). An additional vasovagal was reported in new plasma donors every 17 donations for females and 24 for males, compared with returning donors. The excess risk for a donor new to whole blood having a vasovagal reaction compared to a donor new to plasma was 0.22% for females and 0.63% for males.

Rates for both male and female new plasma donors were significantly lower in 2019-20 compared with 2018‑19. In contrast, the rate for returning males was significantly higher in 2019-20 compared with 2018-19, whereas there was no difference in rates for returning females.

Table 3a: Vasovagal rates in new and returned female and male whole blood donors for FY 2019-2020

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **New or Returned Donor** | | **Females** | | | **Males** | | |  |
| **Events**  **(n)** | **Donations**  **(n)** | **Rate per 10,000** | **Events**  **(n)** | **Donation**  **(n)** | **Rate per**  **10,000** |
| Returned **2019-20** | | 5,438 | 277,567 | 195.92 | 2,103 | 297,549 | 70.68 |
| Returned **2018-19** | | 5,454 | 279,278 | 195.29 | 2,123 | 306,001 | 69.38 |
| New **2019-20** | | 5,452 | 73,098 | 745.85 | 2,792 | 53,261 | 524.21 |
| New **2018-19** | | 4,817 | 68,486 | 703.36 | 2,431 | 50,221 | 484.06 |
| **Comparison groups** | **Relative Risk (95% CI); p value**  [number of donations for an extra event] | | | | **Relative Risk (95% CI); p value**  [number of donations for an extra event] | | |
| New vs returned in 2019-20 | 3.81 (3.67-3.95; p<0.001) [19] | | | | 7.42 (7.01-7.84; p<0.001) [22] | | |
| New 2019 vs 2018 | 1.06 (1.02-1.10; p=0.002) [236] | | | | 1.08 (1.03-1.14; p=0.003) [249] | | |
| Returning 2019 vs 2018 | 1.00 (0.97-1.04; p=0.87) | | | | 1.01 (0.96-1.08; p=0.55) | | |

Table 3b: Vasovagal rates in new and returned female and male plasma donors for FY 2018-19 and 2019-20

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **New or Returned Donor** | | | **Females** | | | | |  |  | | **Males** | | |  | |
| **Events**  **(n)** | | **Donations**  **(n)** | | **Rate per 10,000** | | **Events**  **(n)** | **Donations**  **(n)** | | | **Rate per 10,000** | | |
| **Returned 2019-20** | | 3,788 | | 314,054 | | 120.62 | | | 1,655 | 439,562 | | 37.65 | | | |
| **Returned 2018-19** | | 3,228 | | 275,723 | | 117.07 | | | 1,316 | 402,056 | | 32.73 | | | |
| **New 2019-20** | | 2,818 | | 38,944 | | 723.60 | | | 1,400 | 30,343 | | 461.39 | | | |
| **New 2018-19** | | 3,145 | | 37,966 | | 828.37 | | | 1,514 | 29,921 | | 506.00 | | | |
| **Comparison groups** | **Relative Risk (95% CI); p value**  [number of donations for an extra event] | | | | | | | | **Relative Risk (95% CI); p value**  [number of donations for an extra event] | | | | | |
| **New vs Returned in 2019-20** | | | 6.00 (5.72-6.29; p<0.001) [17] | | | | | | 12.25 (11.42-13.14; p<0.001) [24] | | | | | | |
| **New Plasma vs New Whole blood in 2019-20** | | | 0.97 (0.93-1.01; p=0.18) [450] | | | | | | 0.88 (0.83-0.94; p<0.001) [160] | | | | | | |
| **Returned 2019-20 vs 2018-19** | | | 1.03 (0.98-1.08; p=0.21) | | | | | | 1.15 (1.07-1.24; p<0.001) | | | | | | |
| **New 2019-20 vs 2018-19** | | | 0.87 (0.83-0.92; p<0.001) [96] | | | | | | 0.91 (0.85-0.98; p=0.01) [225] | | | | | | |

**Donor age and gender**

The risk of a vasovagal is higher in females than males across all age groups and reduces with age in both groups (Figure 1). Whilst the lower rates observed in older donors are largely attributed to donation experience, an analysis of new donors less than 30 years compared with those 30 or older, demonstrates that the younger cohort continued to have a significantly higher rate of vasovagal for both whole blood (for females 1069.94 vs 526.24; for males 813.82 vs 365.25; p<0.001) and plasma (for females 897.65 vs 595.37; for males 638.16 vs 360.64; p<0.001), suggesting age as an independent risk (Table 3c).

Figure 1: Vasovagal rate per 10,000 donations (across all donation types) for males and females by age group for 2019-20

Table 3c: Vasovagal rates for new donors aged less than 30 and 30 years and over

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Females** | | | | | | | |  |  | | | **Males** | | |  | |
| **Vasovagal events (n)** | | | | **Donations**  **(n)** | | **Rate per 10,000 donations** | **Vasovagal events (n)** | | | | **Donations (n)** | | | **Rate per 10,000 donations** | | |
| Whole blood <30  Whole blood ≥ 30 | | 3,159  2,293 | | 29,525  43,573 | | 1069.94  526.24 | | 1,536  1,256 | | | 18,874  34,387 | | | 813.82  365.25 | | |
| Plasmapheresis <30 | | 1,483 | | 16,521 | | 897.65 | | 703 | | | 11,016 | | | 638.16 | | |
| Plasmapheresis ≥30 | | 1,335 | | 22,423 | | 595.37 | | 697 | | | 19,327 | | | 360.64 | | |
| **Comparison cohorts Relative Risk (95% CI); p value** | | | | | | | | **Relative Risk (95% CI); p value** | | | | | | | | | |
|  | | | [number of donations for an extra event] | | | | | [number of donations for an extra event] | | | | | | | | | |
| Whole blood <30 vs ≥30 | 2.03 (1.93-2.14; p<0.001) [19] | | | | | | | 2.23 (2.07-2.40; p<0.001) [23] | | | | | | | | | |
| Plasma, <30 vs ≥30 | 1.51 (1.40-1.62; p<0.001) [33] | | | | | | | 1.77 (1.60-1.96; p<0.001) [36] | | | | | | | | | |
| Females vs Males whole blood <30  Females vs Males plasma <30 | 1.31 (1.24-1.39; p<0.001) [39]  1.41 (1.29-1.53; p<0.001) [39] | | | | | | | | | | | | | | | | |

* + 1. **Vasovagal events associated with loss of consciousness and or injury**

Table 4a provides rates of vasovagal events by location and if associated with loss of consciousness and/or injury. Approximately 90% of all vasovagal reactions occurred on-site. In general rates of vasovagal events with loss of consciousness in 2019-20 overall, were similar to those in 2018-19 (13.61 vs 13.26 per 10,000 donations: RR: 1.03; 95% CI: 0.97-1.09; p=0.41). Events occurring on-site were less likely to be associated with loss of consciousness (6.9% vs 16.0%; RR: 0.43; 95% CI 0.39- 0.47; p<0.001) and those sustaining loss of consciousness, had a lower rate of injury if the event occurred on-site (2.3% vs 11.24%; RR: 0.21; 95% CI 0.14-0.31; p<0.001).

In 2019-20 there were 55 reports (0.35 per 10,000 donations) of vasovagal reactions occurring whilst driving, approximately half were in association with apheresis. The total rate was down from 0.52 per 10,000 donations in the 2018-19 FY. In 2019-20, five motor vehicle accidents without long lasting injury were reported in association with these events.

Whilst donors are encouraged to report adverse events that occur after leaving the donor centre, it is likely that minor off-site events are under-reported. Data may therefore overstate both the proportion of events that occur on-site and the association between off-site events and loss of consciousness and/or injury. In general rates of vasovagal events with loss of consciousness in 2019-20 overall, were similar to those in 2018-19 (13.61 vs 13.26 per 10,000 donations: RR: 1.03; 95% CI: 0.97-1.09; p=0.41) (Table 4b).

Table 4a: Vasovagal events per 10,000 donations\* by donation category for FY 2019-20

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Event | | | | Whole Blood n=701,475 | | | Plasmapheresis n=822,903 | | | | | | | Plateletpheresis n=27,501 | | | | | | | | Total  n=1,551,879 | | | |
|  |  |  | | **n** | | **Rate per 10,000** | | **n** | | **Rate per 10,000** | | | **n** | | | | | **Rate per 10,000** | | | **n** | | | **Rate per 10,000** | |
| On-site vasovagal reaction | Without LOC | | No injury | 13,338 | | 190.14 | | | 8,135 | | 98.86 | | | | 314 | | | | 114.18 | | | | 21,787 | | 140.39 |
| Injury | 2 | | 0.03 | | | 4 | | 0.05 | | | | 0 | | | | 0.00 | | | | 6 | | 0.04 |
| With LOC | | No injury | 1,009 | | 14.38 | | | 537 | | 6.53 | | | | 20 | | | | 7.27 | | | | 1,566 | | 10.09 |
| Injury | 30 | | 0.43 | | | 7 | | 0.09 | | | | 0 | | | | 0.00 | | | | 37 | | 0.24 |
| Total | | | 14,370 | | 204.85 | | | 8,679 | | 105.47 | | | | 334 | | | | 121.45 | | | | 23,383 | | 150.68 |
| Off-site vasovagal reaction | Without LOC | | No injury | 1,196 | | 17.05 | | | 935 | | 11.36 | | | | | 20 | | | 7.27 | | | | 2,151 | | 13.86 |
| Injury | 3 | | 0.04 | | | 0 | | 0.00 | | | | | 0 | | | 0.00 | | | | 3 | | 0.02 |
| With LOC | | No injury | 271 | | 3.86 | | | 92 | | 1.12 | | | | | 0 | | | 0.00 | | | | 363 | | 2.34 |
| Injury | 30 | 0.43 | | | | 16 | | | 0.19 | | | | | 0 | | | 0.00 | | | 46 | | 0.30 |
| Total | | | 1,498 | 21.36 | | | | 1,043 | | | 12.67 | | | | | 20 | | | 7.27 | | | 2,561 | | 16.50 |
| Total | onsite and offsite | | | 15,785 | 225.03 | | | | 9,661 | | | 117.40 | | | | | 352 | | | 128.00 | | | 25,798 | | 166.24 |

*\*A single donation can be associated with more than one vasovagal event. The totals values may be less than the sum of the column values as the totals adjusts for those donations which have more than one vasovagal event, and will only count that donation once.*

Table 4b: Rates of vasovagal events with loss of consciousness per 10,000 donations 2016-17 to 2019-20

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Donation Category** | **FY 2016-17** | | **FY 2017-18** | | **FY 2018-19** | | **FY 2019-20** | | **Comparison 19/20 with 18/19** | |
|  | **n** | **Rate per 10,000** | **n** | **Rate per 10,000** | **n** | **Rate per 10,000** | **n** | **Rate per 10,000** | **Relative Risk (95% CI)** | **P value** |
| **Whole Blood** | 1,633 | 22.91 | 1,384 | 19.76 | 1,224 | 17.39 | 1,340 | 19.10 | 1.10 (1.02-1.19) | p=0.02 |
| **Plasmapheresis** | 415 | 7.17 | 543 | 8.40 | 718 | 9.63 | 752 | 9.14 | 0.95 (0.86-1.05) | p=0.32 |
| **Plateletpheresis** | 13 | 4.02 | 19 | 6.84 | 19 | 6.52 | 20 | 7.27 | 1.11 (0.60-2.09) | p=0.73 |
| **Total** | 2,061 | 15.56 | 1,946 | 14.15 | 1,961 | 13.26 | 2,112 | 13.61 | 1.03 (0.97-1.09) | p=0.41 |

* + 1. **Donor adverse events requiring external referral**

The overall rate of events requiring external care has significantly reduced from 8.14 per 10,000 in 2018-19 FY to 6.97 per 10,000 in 2019-20 (RR: 0.86; 95%CI: 0.79-0.93; p<0.001) (Table 5). Vasovagal reactions continue to remain the single most common event associated with a hospital attendance; approximately 87% and 71% of whole blood and plasmapheresis events respectively.

Table 5: Rates for donor adverse events requiring external care (per 10,000 donations) for 2019-20 and rate change from 2018-19

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Donation type** | **GP**  **attendance\*** | | **Ambulance attendance^** | | **Hospital attendance\*** | | | **Total** |  |
|  | **Event (n)** | **Rate per 10,000**  **(change)** | **Event (n)** | **Rate per 10,000**  **(change)** | | **Event (n)** | **Rate per 10,000**  **(change)** | **Event (n)** | **Rate per 10,000**  **(change)** |
| Whole Blood | 264 | 3.76 | 68 | 0.97 | | 208 | 2.97 | 540 | 7.70 |
|  |  | (-1.51) |  | (+0.08) | |  | (-0.47) |  | (-1.9) |
| Plasmapheresis | 279 | 3.39 | 35 | 0.43 | | 216 | 2.62 | 530 | 6.44 |
|  |  | (-0.61) |  | (-0.07) | |  | (+0.27) |  | (-0.41) |
| Plateletpheresis | 6 | 2.18 | 1 | 0.36 | | 4 | 1.45 | 11 | 4.00 |
|  |  | (-1.25) |  | (+0.36) | |  | (-0.95) |  | (-1.84) |
| **Total** | 549 | 3.54 | 104 | 0.67 | | 428 | 2.76 | 1,081 | 6.97 |
|  |  | (-1.05) |  | (-0.01) | |  | (-0.11) |  | (-1.17) |

*\*Initiated by Lifeblood or donor.*

*^Attendance by ambulance not requiring transfer to hospital.*

# Conclusion

In what has been a challenging year for our donor centres, staff and donors, Lifeblood has continued to remain vigilant and responsive to managing donor safety. This includes the close clinical oversight of the transition to the new plasmapheresis platform and ensuring the safety of our donors during the COVID-19 pandemic.

An increase in the total adverse event rate was observed in 2019-20 compared with 2018-19 (404.30 vs 325.50 per 10,000 donations). This was primarily a result of the increase in plasmapheresis phlebotomy-related events and citrate reactions and whole blood vasovagal reactions. The increases are in predominantly mild events, given that there has been a concurrent significant decrease in rates for events requiring external care overall. With the implementation of a tool-kit of phlebotomy improvement measures including a standardised way to secure the venepuncture needle, since July 2019 there has been a progressive reduction in the haematoma and painful arm rates. It is anticipated that rates will improve further in 2020-21 as both staff and donors become more experienced with the new plasmapheresis platform and recently implemented initiatives take effect. As the new apheresis machine platform provides a larger dose of citrate at the beginning of the procedure, we are planning further work on understanding the efficacy of calcium supplementation in our apheresis donors including optimal dose timing, given blood levels take time to peak post dosage.

**Key findings of the 2019-20 donor vigilance report:**

1. **Vasovagal rates:**

Vasovagal rates associated with plasmapheresis were significantly reduced compared with 2018-19. This is primarily attributed to the transition to the new plasmapheresis machine, with some of the effect relating to the higher proportion of experienced plasma donors in 2019-20.

Vasovagal rates associated with whole blood donation significantly increased, however rates of events associated with injury did not increase. The increase in vasovagal rates is attributed in part to the higher proportion of new donors in 2019-20. The remaining increase is that observed in the new donor cohort and may relate to reduced compliance with in-centre water loading and applied muscle tensing exercises. Lifeblood will enhance communication around these strategies which have previously been shown to be effective at reducing vasovagal reactions.

1. **Phlebotomy injuries** **and infiltration/extravasation events:**

Plasmapheresis rates for haematoma, painful arm and infiltration/extravasation events were higher in the 2019‑20 period compared with the previous year. This is again attributed primarily to the implementation of the new platform. A smaller contribution of the change relates to donor demographics and possibly to a lesser extent, ongoing staff hypervigilance following the change to the haematoma reporting definitions in September 2017. With the implementation of a tool-kit of phlebotomy improvement measures including a standardised way to secure the venepuncture needle, since July 2019 there has been a progressive reduction in the haematoma and painful arm rates. It is anticipated that rates will improve further in 2020-21 as both staff and donors become more experienced with the new platform and recently implemented initiatives take effect.

Lifeblood’s donor vigilance system will continue to evolve to improve the collection and reporting of data which can inform targeted interventions, research and support process evaluation, to ensure that blood donation remains as safe as possible.

# APPENDIXES

### Appendix 1: Glossary

|  |  |
| --- | --- |
| **Term** | **Description** |
| Australian Haemovigilance Minimum Data Set | The [Australian Haemovigilance Minimum Data Set](https://www.blood.gov.au/haemovigilance-reporting) (AHMDS) provides data definitions and elements in line with international and national standards for haemovigilance data collection and reporting. The first edition of the AHMDS (known as the 2010 National Haemovigilance Data Dictionary) is superseded by the 2015 AHMDS. |
| Haemovigilance | A set of surveillance procedures covering the entire blood transfusion chain, from the donation and processing of blood and its components, to their provision and transfusion to patients, to their follow-up. It includes monitoring, reporting, investigating and analysing adverse events related to the donation, processing and transfusion of blood, as well as development and implementation of recommendations to prevent the occurrence or recurrence of adverse events.  [National Safety and Quality Health Service Standards, Second Edition](https://www.safetyandquality.gov.au/sites/default/files/2021-05/national_safety_and_quality_health_service_nsqhs_standards_second_edition_-_updated_may_2021.pdf) |
| Attempted donation | An attendance that includes a donation needle-in regardless of whether the target volume was collected.  If the donor has a finger-prick test and/or venous sample but does not have a donation needle inserted, this is not considered an attempted donation. |
| New or first-time whole blood donor | No prior whole blood attempts. Donors may have previously attempted a plasmapheresis donation. |
| Returned whole blood donor | Previously attempted at least one whole blood donation. These donors may or may not have made an apheresis donation in the past. |
| New or first-time plasmapheresis donor | No prior plasma attempts. Donors may have attempted whole blood in the past. |
| Returned plasmapheresis donor | Previously attempted at least one plasmapheresis donation. These donors may or may not have attempted whole blood in the past. |

### Appendix 2: State/territory haemovigilance process improvement

In 2019-20, state/territory departments of health continue to improve their progress for haemovigilance data collection and reporting.

#### NSW

During the reporting period, NSW Health implemented a staged transition to a new incident management platform ims+, resulting in two different datasets. Additional data fields in ims+ has led to more incident notifications containing more information, and capacity to match incidents with the AHMDS.

In direct response to the challenges experienced with the completeness of information within the notifications, Blood Watch published Haemovigilance IIMS reporting resources in July 2019, to improve the quality of notifications. Review of the 2019-2020 data demonstrates a significant uptake of the use of the resources and subsequent improvement in complete notifications.

#### VIC

Review of STIR reporting forms has included the introduction of questions, in appropriate forms (IBCT, near miss, WBIT), relating to errors associated with the use of electronic medical records.

From 1 July 2020, STIR commenced accepting reports of RhD isoimmunisations and hypotensive reactions. Along with these changes we updated our STIR reporting guideline.

In September 2020, STIR had the first launch of the Annual report for 2018-19, by virtual meeting.

Dissemination of information from STIR includes the continued use of Bulletins to health services describing events that may impact patient care and presentations at conferences: an oral presentation on incorrect blood component transfused events as reported to STIR was given at ISBT Regional Congress in December (Virtual).

#### QLD

The strategies implemented across hospitals over the reporting period include education activities such as:

* clinician workshops and education sessions on the administration and monitoring of blood and blood products, to minimise the risks associated with the administration of blood and blood products and to alert clinical staff to early signs and symptoms of adverse reactions to transfusions
* inclusion of the Australian Red Cross Lifeblood information packs at orientation programs for new clinical staff
* regular conduct of Blood Management Committee meetings, reviewing best practice and adverse event cases
* completion of the BloodSafe Clinical Transfusion Practice Module/Refresher (5 modules)
* investigation of transfusion reactions by Haematology, Pathology Blood Bank and Transfusion Clinical Nurse Consultant
* improved management and reporting of Lifeblood notifications regarding initial machine positive results for patients.

#### SA

There are currently a number of haemovigilance-related activities underway that are focused on system, education and quality improvement:

* The Department has been monitoring the utilisation of red blood cells by inpatients since 2006 through the SA Blood Utilisation Study. The information from this study has been incorporated into a Reporting Tool which allows major metropolitan hospitals to better understand their red cell usage patterns.
* The implementation of the Enterprise Patient Administration System (EPAS) across SA Health required the development of clinician friendly blood and blood product transfusion order sets that meet current national transfusion guidelines and legislative requirements.
* The BloodSafe Transfusion Nurse Consultants conduct regular audits to monitor variability in ordering practices and compliance with Standard 7 haemovigilance activities.
* The review of SLS to ensure it remains in line with the National Haemovigilance Minimum Dataset involved the development of a detailed topic guide to educate transfusion nurses on the changes. The guide included detailed definitions, tips for accurate reporting, information for managers and a section on the reporting requirements for transfusion reactions that are Sentinel events, or require internal and/or external reporting.
* The SA Blood Management Council has recommended that all medical, nursing, and support staff complete training provided by BloodSafe eLearning Australian with the aim of improving the recognition and reporting of adverse events.

#### WA

The need for progress and improvement in the reporting area had been flagged following the 2018-19 report. This year’s report is presented in two sections. The first part providing insight into and analysis of transfusion-related adverse events reported in the last year. The second part looks at reporting trends over the last five years. For the first time the 2019-20 report contains recommendations on observed trends. A strong focus was placed on moving away from simply presenting numbers and towards a more informative report.

WA gathered further information from the hospitals regarding Allergic reactions as these are WA’s most commonly reported adverse event. Based on the information provided WA were able to make recommendations involving the identification and follow up treatment of these events. WA took a closer look at antibodies which are commonly implicated in DSTR and DHTR adverse events. Case studies were more thoroughly researched and dispersed within the report to link to the relevant data.

#### TAS

The Tasmanian Health Service Safety Learning and Reporting System (SLRS) system records and ensures safety events throughout the system, including blood safety events, are followed up and appropriately actioned.

New IT systems introduced at the Launceston General Hospital to streamline ordering and receipt of blood products which reduces risk of transcription errors.

#### NT

The occurrence rate of reported transfusion rates during the period of 2019 – 2020 has remained steady in comparison to the 2018 – 2019 data.

All of the reported transfusion reactions are investigated and discussed at the Transfusion Incident Review Group (TIRG) meetings, and when deemed appropriate, at the NT Transfusion Committee (NTTC) meetings.

Staff and facility education and support remains paramount in accordance with NSQHS Standard 7, which assists in keeping the number of adverse events to a minimum within this jurisdiction.

#### ACT

The ACT has been actively involved in haemovigilance since 2003. An ACT wide transfusion practitioners’ network was implemented in 2019 to support safe and appropriate transfusion practice across the Territory. This group includes representation from both public and private hospitals and laboratories.

Through the successful implementation of Patient Blood Management strategies across the ACT, packed red blood cell usage has reduced by 34% since 2012. This reduction in usage will have had a corresponding impact on reducing transfusion-related incidents. The most common incidents in the ACT are febrile non haemolytic reactions which are not reported to either STIR or the national haemovigilance program.

88% of fresh blood products are distributed via the major public hospitals.

# ABBREVIATIONS

ABO The human red cell ABO blood group system

ACT Australian Capital Territory

AE Adverse event

AHMDS Australian Haemovigilance Minimum Data Set

AHTR Acute haemolytic transfusion reaction (other than ABO incompatibility)

Allergic Allergic reaction

ATR Acute transfusion reactions

CI Confidence interval

DAE Donor adverse event

DHTR Delayed haemolytic transfusion reaction

DSTR Delayed serologic reaction

FNHTR Febrile non-haemolytic transfusion reaction

FY Financial year

GP General Practitioner

HAC Haemovigilance Advisory Committee

IBCT Incorrect blood component transfused

IHN International Haemovigilance Network

Lifeblood Australian Red Cross Lifeblood

ISBT International Society for Blood Transfusion

LOC Loss of consciousness

NBA National Blood Authority

Non-SAE Non-serious adverse event

NHDD National Haemovigilance Data Dictionary

NSQHS National Safety and Quality Health Service

NSW New South Wales

NT Northern Territory

PTP Post transfusion purpura

QLD Queensland

RBC Red blood cell

RR Relative risk

SA South Australia

SAE Serious adverse event

SLRS Tasmanian Health Service Safety Learning and Reporting System

STIR Serious Transfusion Incident Reporting

TACO Transfusion-associated circulatory overload

TAD Transfusion associated dyspnoea

TAS Tasmania

TRALI Transfusion-related acute lung injury

TTI Transfusion-transmitted infection

VIC Victoria

VVR Vasovagal rate

WA Western Australia

# ACKNOWLEDGEMENTS LIST

**National Blood Authority Haemovigilance Advisory Committee (HAC)**

**Members**

Associate Professor Alison Street NBA Board member and NBA appointed HAC Chair

Mr Brett Aitken Australian Private Hospitals Association

Mr Geoffrey Bartle Consumer Representative

Ms Linley Bielby VIC Health

Ms Maria Burgess ACT Health

Dr James Daly Australian Red Cross Lifeblood

Dr Chris Hogan Non-affiliated Haematologist

Ms Penny O’Beid NSW Health

Dr Sharon Nowrojee WA Health

Associate Professor David Roxby Australian and New Zealand Society of Blood Transfusion

Dr Neil Everest Commonwealth Department of Health

Professor Erica Wood Non-affiliated Haematologist

Associate Professor Lilon Bandler NBA Patient Blood Management Advisory Committee Chair

**Expert Advisors**

Dr Heather Buchan Australian Commission on Safety and Quality in Health Care

Dr Angela Gowland Therapeutic Goods Administration

Dr Adrian Webster Australian Institute of Health and Welfare

**National Blood Authority**

Mr John Cahill Chief Executive

Ms Sandra Cochrane Senior Advisor, Blood and Data Services

Ms Suzie Cong Senior Data Analyst, Blood and Data Services

Ms Leia Earnshaw Assistant Director, Haemovigilance, Blood and Data Services

**Australian Government and State and Territory contributors**

NSW Health Clinical Excellence Commission Blood Watch Program

VIC Department of Health and Human Services Blood Matters Program

QLD Health

SA Health BloodSafe Program

WA Department of Health

TAS Department of Health and Human Services

ACT Health

NT Department of Health

**SECTION 2 – DONOR VIGILANCE was contributed by the Australian Red Cross Lifeblood**

1. Based on minimum collection of 450mL for males and females 2016-17 to 2019-20 [↑](#footnote-ref-1)
2. Based on minimum collection of 422mL for females and 488 for males excluding anticoagulant 2016-17 to 2019-20 [↑](#footnote-ref-2)
3. Based on collection of double-dose platelet 2016-17 to 2019-20 [↑](#footnote-ref-3)
4. Relative Risk [↑](#footnote-ref-4)
5. Confidence Interval [↑](#footnote-ref-5)